Early Effects of Different Cytostatic Protocols for Head and Neck Cancer on Oncogene Activation in Animal Experiments

Arpad Németh, E. Nadasi, Z. Gyöngyi, L. Olasz, Z. Nyarady, A. Ember, A. Kvarda, L. Bujdoso, I. Arany, I. Kiss, I. Csejtey, I. Ember

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In vivo investigations on oncogenes and oncosuppressor genes may provide new findings on the potential carcinogenic effects of various cytostatic protocols inducing secondary tumours of the head and neck. Further surgeries are often necessary due to regional recurrence after the Cisplatin-supplemented BVM (Bleomycin, Vincristine, Methotrexate) protocol in the treatment of human head and neck tumours. Our earlier studies have illustrated the carcinogenic and mutagenic potential of Cisplatin. The effect of Cisplatin on the alteration of different onco- and suppressor genes has also been proven. Our present study aimed at investigating the early effects of the BVM and the CFu (Cisplatin, 5-Fluorouracil) protocols on early oncogene and tumour supressor gene expressions in mice. Body weight equivalent amounts of cytostatics were administered intraperitoneally to 6- to 8-week-old, inbred, female CBA/Ca mice. Twenty-four, 48 and 72 hours after the treatment, RNA was isolated from the target organs and the quantitative expression of c-myc, Ha-ras and p53 genes were examined. The protocols caused detectable changes. A "short-term" in vivo test, the 24-hour examination of gene expression, is suitable for detecting early effects of carcinogen exposure. The alterations of gene expression, caused by the Cisplatin-containing protocol, draw attention to the probable role of Cisplatin in the development of regional recurrence and to the possibility of prevention.

Original languageEnglish
Pages (from-to)4831-4835
Number of pages5
JournalAnticancer Research
Volume23
Issue number6 C
Publication statusPublished - Nov 2003

Fingerprint

Cytostatic Agents
Head and Neck Neoplasms
Oncogenes
Cisplatin
Bleomycin
Vincristine
Gene Expression
Methotrexate
Neck
Head
Recurrence
Neoplasms
Inbred CBA Mouse
ras Genes
p53 Genes
Clinical Protocols
Tumor Suppressor Genes
Fluorouracil
Carcinogens
Body Weight

Keywords

  • Chemotherapy
  • Gene expression
  • Head and neck cancer
  • Secondary tumours

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Németh, A., Nadasi, E., Gyöngyi, Z., Olasz, L., Nyarady, Z., Ember, A., ... Ember, I. (2003). Early Effects of Different Cytostatic Protocols for Head and Neck Cancer on Oncogene Activation in Animal Experiments. Anticancer Research, 23(6 C), 4831-4835.

Early Effects of Different Cytostatic Protocols for Head and Neck Cancer on Oncogene Activation in Animal Experiments. / Németh, Arpad; Nadasi, E.; Gyöngyi, Z.; Olasz, L.; Nyarady, Z.; Ember, A.; Kvarda, A.; Bujdoso, L.; Arany, I.; Kiss, I.; Csejtey, I.; Ember, I.

In: Anticancer Research, Vol. 23, No. 6 C, 11.2003, p. 4831-4835.

Research output: Contribution to journalArticle

Németh, A, Nadasi, E, Gyöngyi, Z, Olasz, L, Nyarady, Z, Ember, A, Kvarda, A, Bujdoso, L, Arany, I, Kiss, I, Csejtey, I & Ember, I 2003, 'Early Effects of Different Cytostatic Protocols for Head and Neck Cancer on Oncogene Activation in Animal Experiments', Anticancer Research, vol. 23, no. 6 C, pp. 4831-4835.
Németh A, Nadasi E, Gyöngyi Z, Olasz L, Nyarady Z, Ember A et al. Early Effects of Different Cytostatic Protocols for Head and Neck Cancer on Oncogene Activation in Animal Experiments. Anticancer Research. 2003 Nov;23(6 C):4831-4835.
Németh, Arpad ; Nadasi, E. ; Gyöngyi, Z. ; Olasz, L. ; Nyarady, Z. ; Ember, A. ; Kvarda, A. ; Bujdoso, L. ; Arany, I. ; Kiss, I. ; Csejtey, I. ; Ember, I. / Early Effects of Different Cytostatic Protocols for Head and Neck Cancer on Oncogene Activation in Animal Experiments. In: Anticancer Research. 2003 ; Vol. 23, No. 6 C. pp. 4831-4835.
@article{f61621ad47b3476e897aa02a3ef383fc,
title = "Early Effects of Different Cytostatic Protocols for Head and Neck Cancer on Oncogene Activation in Animal Experiments",
abstract = "In vivo investigations on oncogenes and oncosuppressor genes may provide new findings on the potential carcinogenic effects of various cytostatic protocols inducing secondary tumours of the head and neck. Further surgeries are often necessary due to regional recurrence after the Cisplatin-supplemented BVM (Bleomycin, Vincristine, Methotrexate) protocol in the treatment of human head and neck tumours. Our earlier studies have illustrated the carcinogenic and mutagenic potential of Cisplatin. The effect of Cisplatin on the alteration of different onco- and suppressor genes has also been proven. Our present study aimed at investigating the early effects of the BVM and the CFu (Cisplatin, 5-Fluorouracil) protocols on early oncogene and tumour supressor gene expressions in mice. Body weight equivalent amounts of cytostatics were administered intraperitoneally to 6- to 8-week-old, inbred, female CBA/Ca mice. Twenty-four, 48 and 72 hours after the treatment, RNA was isolated from the target organs and the quantitative expression of c-myc, Ha-ras and p53 genes were examined. The protocols caused detectable changes. A {"}short-term{"} in vivo test, the 24-hour examination of gene expression, is suitable for detecting early effects of carcinogen exposure. The alterations of gene expression, caused by the Cisplatin-containing protocol, draw attention to the probable role of Cisplatin in the development of regional recurrence and to the possibility of prevention.",
keywords = "Chemotherapy, Gene expression, Head and neck cancer, Secondary tumours",
author = "Arpad N{\'e}meth and E. Nadasi and Z. Gy{\"o}ngyi and L. Olasz and Z. Nyarady and A. Ember and A. Kvarda and L. Bujdoso and I. Arany and I. Kiss and I. Csejtey and I. Ember",
year = "2003",
month = "11",
language = "English",
volume = "23",
pages = "4831--4835",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6 C",

}

TY - JOUR

T1 - Early Effects of Different Cytostatic Protocols for Head and Neck Cancer on Oncogene Activation in Animal Experiments

AU - Németh, Arpad

AU - Nadasi, E.

AU - Gyöngyi, Z.

AU - Olasz, L.

AU - Nyarady, Z.

AU - Ember, A.

AU - Kvarda, A.

AU - Bujdoso, L.

AU - Arany, I.

AU - Kiss, I.

AU - Csejtey, I.

AU - Ember, I.

PY - 2003/11

Y1 - 2003/11

N2 - In vivo investigations on oncogenes and oncosuppressor genes may provide new findings on the potential carcinogenic effects of various cytostatic protocols inducing secondary tumours of the head and neck. Further surgeries are often necessary due to regional recurrence after the Cisplatin-supplemented BVM (Bleomycin, Vincristine, Methotrexate) protocol in the treatment of human head and neck tumours. Our earlier studies have illustrated the carcinogenic and mutagenic potential of Cisplatin. The effect of Cisplatin on the alteration of different onco- and suppressor genes has also been proven. Our present study aimed at investigating the early effects of the BVM and the CFu (Cisplatin, 5-Fluorouracil) protocols on early oncogene and tumour supressor gene expressions in mice. Body weight equivalent amounts of cytostatics were administered intraperitoneally to 6- to 8-week-old, inbred, female CBA/Ca mice. Twenty-four, 48 and 72 hours after the treatment, RNA was isolated from the target organs and the quantitative expression of c-myc, Ha-ras and p53 genes were examined. The protocols caused detectable changes. A "short-term" in vivo test, the 24-hour examination of gene expression, is suitable for detecting early effects of carcinogen exposure. The alterations of gene expression, caused by the Cisplatin-containing protocol, draw attention to the probable role of Cisplatin in the development of regional recurrence and to the possibility of prevention.

AB - In vivo investigations on oncogenes and oncosuppressor genes may provide new findings on the potential carcinogenic effects of various cytostatic protocols inducing secondary tumours of the head and neck. Further surgeries are often necessary due to regional recurrence after the Cisplatin-supplemented BVM (Bleomycin, Vincristine, Methotrexate) protocol in the treatment of human head and neck tumours. Our earlier studies have illustrated the carcinogenic and mutagenic potential of Cisplatin. The effect of Cisplatin on the alteration of different onco- and suppressor genes has also been proven. Our present study aimed at investigating the early effects of the BVM and the CFu (Cisplatin, 5-Fluorouracil) protocols on early oncogene and tumour supressor gene expressions in mice. Body weight equivalent amounts of cytostatics were administered intraperitoneally to 6- to 8-week-old, inbred, female CBA/Ca mice. Twenty-four, 48 and 72 hours after the treatment, RNA was isolated from the target organs and the quantitative expression of c-myc, Ha-ras and p53 genes were examined. The protocols caused detectable changes. A "short-term" in vivo test, the 24-hour examination of gene expression, is suitable for detecting early effects of carcinogen exposure. The alterations of gene expression, caused by the Cisplatin-containing protocol, draw attention to the probable role of Cisplatin in the development of regional recurrence and to the possibility of prevention.

KW - Chemotherapy

KW - Gene expression

KW - Head and neck cancer

KW - Secondary tumours

UR - http://www.scopus.com/inward/record.url?scp=10744220358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744220358&partnerID=8YFLogxK

M3 - Article

C2 - 14981932

AN - SCOPUS:10744220358

VL - 23

SP - 4831

EP - 4835

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6 C

ER -